- Home
- NMFC vs AUPH Comparison
NMFC vs AUPH Comparison
Compare NMFC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMFC
- AUPH
- Stock Information
- Founded
- NMFC 2010
- AUPH 1993
- Country
- NMFC United States
- AUPH Canada
- Employees
- NMFC N/A
- AUPH N/A
- Industry
- NMFC Finance/Investors Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NMFC Finance
- AUPH Health Care
- Exchange
- NMFC Nasdaq
- AUPH Nasdaq
- Market Cap
- NMFC 1.2B
- AUPH 1.4B
- IPO Year
- NMFC 2011
- AUPH 1999
- Fundamental
- Price
- NMFC $10.62
- AUPH $12.40
- Analyst Decision
- NMFC Hold
- AUPH Strong Buy
- Analyst Count
- NMFC 2
- AUPH 4
- Target Price
- NMFC $10.50
- AUPH $12.25
- AVG Volume (30 Days)
- NMFC 406.4K
- AUPH 1.8M
- Earning Date
- NMFC 10-29-2025
- AUPH 07-31-2025
- Dividend Yield
- NMFC 12.08%
- AUPH N/A
- EPS Growth
- NMFC N/A
- AUPH N/A
- EPS
- NMFC 0.77
- AUPH 0.42
- Revenue
- NMFC $355,675,000.00
- AUPH $260,111,000.00
- Revenue This Year
- NMFC N/A
- AUPH $16.92
- Revenue Next Year
- NMFC N/A
- AUPH $14.29
- P/E Ratio
- NMFC $13.81
- AUPH $29.81
- Revenue Growth
- NMFC N/A
- AUPH 25.59
- 52 Week Low
- NMFC $8.84
- AUPH $6.42
- 52 Week High
- NMFC $12.36
- AUPH $12.82
- Technical
- Relative Strength Index (RSI)
- NMFC 57.59
- AUPH 66.76
- Support Level
- NMFC $10.47
- AUPH $11.57
- Resistance Level
- NMFC $10.71
- AUPH $12.46
- Average True Range (ATR)
- NMFC 0.12
- AUPH 0.37
- MACD
- NMFC 0.03
- AUPH -0.09
- Stochastic Oscillator
- NMFC 78.57
- AUPH 66.51
About NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.